-
Mashup Score: 0Dato-DXd Shows Promise as a More Tolerable ADC in HER2-Negative mBC - 12 hour(s) ago
During a Case-Based Roundtable® event, Igor Makhlin, MD, discussed with participants their impressions of datopotamab deruxtecan as therapy for patients with HR-positive, HER2-negative breast cancer, and the sequential use of multiple antibody-drug conjugates.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 0
During a live Community Case Forum event in partnership with the Minnesota Society of Clinical Oncology, Roberto A. Leon-Ferre, MD, discussed drugs targeting PIK3CA alterations in patients with ER+ metastatic breast cancer.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 2Supporting Patients With Breast Cancer: How Nurses Can Maximize Opportunities for Connection | Cancer Nursing Today - 3 day(s) ago
Panelists discuss how nurses can connect with patients who are receiving breast cancer treatment and how reducing treatment time benefits patients and clinics.
Source: cancernursingtoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 25Confirmation of large BRCA2 reversion deletions leading to reconstituted in-frame transcripts detected via circulating tumor DNA - 4 day(s) ago
Acquisition of BRCA1/2 “reversion” mutations that restore the open reading frame (ORF) has been described as a potential mechanism of resistance to PARP inhibitors (PARPi) and platinum chemotherapy.1,2 In the recent report from Harvey-Jones and colleagues,3 the authors analyzed ctDNA from patients with BRCA-mutated metastatic breast cancer (MBC) during and after PARPi/platinum therapy. They observed that BRCA1/2 reversion mutations were common (60% of patients) and associated with significantly shorter time to progression.
Source: www.annalsofoncology.orgCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 3
Erika Hamilton, MD, discussed findings from the phase 1b/2 ELECTRA study investigating a new oral combination therapy for patients with metastatic breast cancer.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 19Confirmation of large BRCA2 reversion deletions leading to reconstituted in-frame transcripts detected via circulating tumor DNA - 4 day(s) ago
Acquisition of BRCA1/2 “reversion” mutations that restore the open reading frame (ORF) has been described as a potential mechanism of resistance to PARP inhibitors (PARPi) and platinum chemotherapy.1,2 In the recent report from Harvey-Jones and colleagues,3 the authors analyzed ctDNA from patients with BRCA-mutated metastatic breast cancer (MBC) during and after PARPi/platinum therapy. They observed that BRCA1/2 reversion mutations were common (60% of patients) and associated with significantly shorter time to progression.
Source: www.annalsofoncology.orgCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 47Systemic Therapy in Breast Cancer | American Society of Clinical Oncology Educational Book - 6 day(s) ago
Therapeutic advances in breast cancer have significantly improved outcomes in recent decades. In the early setting, there has been a gradual shift from adjuvant-only to neoadjuvant strategies, with a growing focus on customizing post-neoadjuvant treatments through escalation and de-escalation based on pathologic response. At the same time, the transition from a pre-genomic to a post-genomic era, utilizing specific assays in the adjuvant setting and targeted sequencing in the advanced stage, has deepened our understanding of disease biology and aided in identifying molecular markers associated with treatment benefit. Finally, the introduction of new drug classes such as antibody-drug conjugates, and the incorporation in the (neo)adjuvant setting of therapies previously investigated in the advanced stage, like immunotherapy and CDK4-6 inhibitors, poses new challenges in treatment sequencing.
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1
A phase 1 trial is underway to assess the safety and efficacy of BTX-9341, a novel investigational oral degrader of CDK4/6 in HR-positive/HER2-negative breast cancer.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 4
Medical oncologists share clinical practices for selecting and sequencing TROP2-directed antibody-drug conjugates, highlighting ideal candidates for sacituzumab govitecan or datopotamab deruxtecan.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 0TROPiCS-02: Sacituzumab Govitecan in HR+/HER2- Metastatic or Locally Recurrent Breast Cancer - 9 day(s) ago
Experts on breast cancer offer comprehensive insights on findings from the TROPiCS-02 study investigating sacituzumab govitecan in patients with HR+/HER2- metastatic or locally recurrent inoperable breast cancer.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet
Igor Makhlin, MD, of @PennMedicine discussed with participants their impressions of datopotamab deruxtecan as therapy for patients with HR-positive, HER2-negative breast cancer, and the sequential use of multiple antibody-drug conjugates. #BCSM https://t.co/c1bZpVn0bF